Inhibition of Growth of HT-29 Human Colon Cancer Xenografts in Nude Mice by Treatment with Bombesin/Gastrin Releasing Peptide Antagonist (RC-3095)

Sinisa Radulovic, Glenn Miller, rew V. Schally

Research output: Contribution to journalArticle

111 Scopus citations

Abstract

Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 weeks with a [D-Trp6] agonist of luteinizing hormone releasing hormone (LH-RH), somatostatin analogue (RC-160), and bombesin/gastrin releasing peptide antagonist (RC-3095). Some inhibitory effect of [D-Trp6] LH-RH microcapsules releasing 25 μg/day on tumor growth was observed that could be due to sex steroid deprivation, but the inhibition was not statistically significant. Microcapsules of RC-160, releasing 50 μg/day, significantly reduced tumor volume after 21 and 24 days of treatment, but at the end of the experiment the inhibition in tumor volume and weight was not significant. Bombesin/gastrin releasing peptide antagonist RC-3095, at a dose of 20 μg/day administered by daily s.c. injections or by continuous infusion using Alzet osmotic minipumps, had the greatest inhibitory effect on tumor growth. Tumor volume, percentage change in tumor volume, and tumor weights were significantly decreased in both groups treated with RC-3095. This is the first report on inhibition of human colon cancer growth in vivo by bombesin antagonists.

Original languageEnglish (US)
Pages (from-to)6006-6009
Number of pages4
JournalCancer Research
Volume51
Issue number21
StatePublished - Nov 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Inhibition of Growth of HT-29 Human Colon Cancer Xenografts in Nude Mice by Treatment with Bombesin/Gastrin Releasing Peptide Antagonist (RC-3095)'. Together they form a unique fingerprint.

  • Cite this